Genetic engineering and coagulation factors.
It is unfortunate that we cannot report, in the area of coagulation, advances that have been seen in related fields such as thrombolytic therapy. The reported progress (Gold et al, 1984; Van de Werf et al, 1984) with human recombinant tissue plasminogen activator (Pennica et al, 1983) augers well for the application of recombinant technology to the problems faced by patients with coagulation defects. While plasminogen activator is being assessed in an acute therapeutic setting, its use signals a beginning of the application of the technology to abnormalities of the haemostatic mechanism. Chronic administration of coagulation factors for prophylaxis and replacement therapy would appear to be just one more step down the pathway illuminated by the biochemists, microbiologists and cell biologists who have preceded the clinicians in this promising area. There is no record of the use of genetically engineered materials in the treatment of coagulation defects, primarily because the body of knowledge and refined techniques have only recently been acquired. For this reason we have had to project developments in other areas onto the problems that exist for the haemostatically compromised patient. In describing the potential usefulness of these technologies, it is difficult to ascertain where the logical projection, from a fully investigated model system, diverges from flights of imaginative fancy. Cloning projects considered overly ambitious and grandiose at the beginning of this decade are already accomplished feats. The feasibility of gene therapy in the mammalian system has been demonstrated, and trade publications now discuss governmental approval for investigative use of this procedure in 1985. Panels of physicians, scientists and even politicians now seriously contemplate and promulgate views and regulations pertaining to the efficacy and ethics of the use of genetic engineering in the treatment of human disease. The haemophilias will certainly be among the first genetic diseases to be approached with the techniques of recombinant DNA technology. Diagnostic testing, using cloned DNA, is already underway and therapeutic trials are predicted for the near future. Every observer of this rapidly growing field has to define for himself when the future is. For the potential carrier of haemophilia B, the future is now. For the physician managing the patient with a haemophilic inhibitor, the future can't come soon enough. And, for those who are concerned with man's tampering with the gene pools of living things, from viruses to humans, the future comes too quickly to be dealt with in a rational and understanding way.
D000818:Animals; D001327:Autoimmune Diseases / Q000628:therapy; D001778:Blood Coagulation Disorders / Q000175:diagnosis / Q000628:therapy; D001779:Blood Coagulation Factors / Q000235:genetics*; D003001:Cloning, Molecular; D004274:DNA, Recombinant; D005164:Factor IX / Q000235:genetics; D005169:Factor VIII / Q000235:genetics; D005170:Factor X / Q000235:genetics; D005340:Fibrinogen / Q000235:genetics; D005796:Genes; D005818:Genetic Engineering; D006801:Humans; D051379:Mice; D011296:Prenatal Diagnosis; D011516:Prothrombin / Q000235:genetics; D051381:Rats
D001779:Blood Coagulation Factors; D004274:DNA, Recombinant; D011516:Prothrombin; D005169:Factor VIII; D005164:Factor IX; D005170:Factor X; D005340:Fibrinogen